CORDIS
EU research results

CORDIS

English EN
MOLECULAR BASIS OF ANTIBIOTIC TRANSLOCATION

MOLECULAR BASIS OF ANTIBIOTIC TRANSLOCATION

Objective

Multidrug resistant bacteria are now ubiquitous in both hospitals and the larger community. Drug-resistant pathogens are becoming increasingly pervasive, for example, the resurrection of tuberculosis provides one ominous example highlighting the risk associated with evolved drug resistance. Moreover, many pharmaceutical companies abandoned this field and no truly novel active antibacterial compounds are currently in clinical trials. Obviously we need new antibacterial molecules and maybe, novel strategies to develop antibiotics. The novel aspect here is to use state-in-the art techniques to quantify rate limiting steps of individual components involved antibiotic penetration and to validate them at the cellular level. Such a system biology approach identifies bottlenecks of existing antibiotics and might suggest novel antibiotic therapy. In Gram-negative bacteria, where influx and efflux systems located in the Outer Membrane represent a physical bottleneck for any antibiotic to reach a potential target. The aim is to investigate the molecular and cellular mechanisms at the basis of the influx and efflux processes and to teach scientists with different scientific background to go beyond the
classical faculty boarder. Bringing nanotechnology, physics, chemistry, computer modeling, pharmacology, microbiology together will facilitate the transfer of expertise acquired within the network in both academic and industry.
To achieve these goals we propose a training program allowing young researcher to collaborate across traditional faculty boarder. Three partners from the private sector will actively participate, the first one is a SME developing unique nanodevices allowing high-throughput drug screening in the field of electrophysiology, the second one is engaged in developing novel antibiotics and the third one is working on drug screening and characterization. Moreover three global pharmaceutical companies will accept students for secondments.

Coordinator

JACOBS UNIVERSITY BREMEN GGMBH

Address

Campus Ring 1
28759 Bremen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 625 640,18

Administrative Contact

Ronald Kieschnick (Mr.)

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITA DEGLI STUDI DI CAGLIARI

Italy

EU Contribution

€ 663 400,72

THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS

United Kingdom

EU Contribution

€ 285 056,64

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 285 056,64

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany

EU Contribution

€ 222 068,88

UNIVERSITE D'AIX MARSEILLE

France

EU Contribution

€ 255 948,66

UNIVERSITAT BASEL

Switzerland

EU Contribution

€ 261 515,76

BIOVERSYS AG

Switzerland

EU Contribution

€ 261 515,76

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 222 068,88

NANION TECHNOLOGIES GMBH

Germany

EU Contribution

€ 222 068,88

European ScreeningPort GmbH

Germany

Project information

Grant agreement ID: 607694

Status

Closed project

  • Start date

    1 September 2013

  • End date

    31 August 2017

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 3 304 341

  • EU contribution

    € 3 304 341

Coordinated by:

JACOBS UNIVERSITY BREMEN GGMBH

Germany

This project is featured in...